论文部分内容阅读
目的评价吉西他滨单药以及与替吉奥联合治疗局部晚期或转移性胰腺癌的有效率、临床受益反应(评价指标包括患者的疼痛强度、止痛药物消耗量、体力状况评分和体重变化)、生存时间和不良反应。方法回顾性分析2009年1月至2011年10月收治的62例晚期胰腺癌患者,分为吉西他滨单药组(30例)和吉西他滨+替吉奥联合组(32例)。单药组:吉西他滨1 000 mg·m?2、第1,8天,静脉滴注30 min,每3周重复。联合组:吉西他滨用法同单药组,替吉奥口服2次·d??,第1~14天,每3周重复。结果 62例患者均可评价客观疗效,可评价临床受益反应者56例(单药组27例,联合组29例)。单药组和联合组有效率分别为23.3%和31.3%(P<0.05),临床受益率分别为59.2%和72.4%(P>0.05)。2组6个月生存率分别为60.0%和68.7%(P>0.05),1年生存率分别为26.6%和31.2%(P>0.05)。中位无疾病进展时间(PFS)分别为3.9个月和5.4个月(P<0.05),中位总生存时间分别为7.8个月和9.1个月(P>0.05)。2组不良反应比较差异无统计学意义(P>0.05)。结论吉西他滨联合替吉奥与单药吉西他滨治疗晚期胰腺癌安全有效,前者有效率优于后者。在延长生存期方面也显示出一定的优势,但该差异无统计学意义。
Objectives To evaluate the efficacy, gemcitabine benefit response (index of assessment including patient’s pain intensity, pain medication consumption, physical status score and weight change) of gemcitabine monotherapy as well as combined with tigegio in the treatment of locally advanced or metastatic pancreatic cancer, survival time And adverse reactions. Methods Sixty-two patients with advanced pancreatic cancer who were treated from January 2009 to October 2011 were retrospectively analyzed. Patients were divided into gemcitabine monotherapy group (30 cases) and gemcitabine + treatment group (32 cases). Single drug group: Gemcitabine 1 000 mg · m 2, on the first and eighth days, intravenous infusion of 30 min, repeated every 3 weeks. Combination group: gemcitabine use with the single-drug group, for two times orally G · d ??, 1 to 14 days, repeated every 3 weeks. Results All the 62 patients could evaluate the objective curative effect. 56 cases of clinical benefit could be evaluated (27 in the single drug group and 29 in the combined group). The effective rates of single drug group and combined group were 23.3% and 31.3% respectively (P <0.05), and the clinical benefit rates were 59.2% and 72.4% respectively (P> 0.05). The 6-month survival rates of two groups were 60.0% and 68.7%, respectively (P> 0.05). The 1-year survival rates were 26.6% and 31.2% respectively (P> 0.05). The median progression-free time (PFS) was 3.9 months and 5.4 months (P <0.05), respectively, with a median overall survival of 7.8 months and 9.1 months, respectively (P> 0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusions Gemcitabine combined with tirgine and gemcitabine alone is safe and effective in the treatment of advanced pancreatic cancer. The former is superior to the latter in efficiency. In the extension of survival also showed some advantages, but the difference was not statistically significant.